This site is intended for healthcare professionals only

NICE guideline on acute kidney injury

Metformin is first-line drug therapy in type 2 diabetes. A recently published NICE guideline on acute kidney injury reminds us that we should consider this condition in people using metformin, particularly if they are over 65, have an intercurrent illness or take other potentially toxic medications.

by Colin Kenny, GP, Dromore, County Down

NICE has published a guideline document on acute kidney injury (AKI). The document explains the transition of the term acute renal failure to AKI. It also outlines an at-risk population – people with diabetes who are over 65, who have intercurrent illness, or who are using metformin or angiotensin-converting enzyme inhibitors all feature prominently in the guideline.

This advice is clear. Primary care teams should recognise the potential risk, counsel patients carefully, and give them written guidance on what they, and their carers, should do during intercurrent illness, especially if there is a poor urine output. Be clear on drugs to avoid or stop during illness. An ill individual will need urgent referral for investigations and assessment.

To access the full guidance click here (link to external website)

Related content
Hypoglycaemia awareness resources for healthcare professionals
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.